Physician profile
Johnathan M Moore
NPI 1467112250
$8,511.31
in general payments reported to CMS, 2019-2025
22 companies · $2,870 in 2025
The $2,870 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $485 · 2023: $2,361 · 2024: $2,795 · 2025: $2,870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,497 · Education: $529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,496.62 |
| Education | $529.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,157.66 | 2022-2025 | |
| Janssen Biotech, INC. | $1,030.48 | 2023-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $765.70 | 2022-2025 | Sotyktu |
| Ucb, INC. | $664.71 | 2023-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $562.26 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $554.87 | 2022-2025 | Cabtreo, Jublia, Siliq |
| Amgen INC. | $540.81 | 2023-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $478.08 | 2022-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $391.39 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Pfizer INC. | $346.62 | 2022-2025 | |
| Genzyme Corporation | $264.56 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $171.92 | 2022-2025 | |
| Leo Pharma INC. | $129.11 | 2023-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $116.13 | 2024-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $108.84 | 2023-2025 | Ebglyss, Taltz, Olumiant |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $49.99 | 2023-2025 | Opzelura |
| Dermavant Sciences, INC. | $48.07 | 2023-2024 | Vtama |
| Actelion Pharmaceuticals US, INC. | $41.29 | 2025 | Uptravi |
| Helsinn Therapeutics (U.S.), INC. | $27.37 | 2025 | Valchlor |
| Organon LLC | $22.75 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.41 | 2023 | Spevigo |
| Journey Medical Corporation | $18.29 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnathan Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.